by After changing to normal Tyrode with out NaCl (substituted with 140 mM LiCl) and 1 mM CaCl2, 10 M ionomycin (Sigma Aldrich) was added (Rmax). The analysis of Ca2+transients in neonatal rat cardiomyocytes (NRCs) demonstrated that TRPC4 and TRPC4 affected Ca2+cycling in beating cardiomyocytes with both splice variations inducing an elevation in the Ca2+transient amplitude at baseline and TRPC4 increasing the Ca2+peak during angiotensin II (Ang II) stimulation. NRCs infected with TRPC4 (Ad-C4) also responded with a continual Ca2+influx when treated with Ang II under non-pacing conditions. Consistent with the Ca2+data, NRCs infected with TRPC4 (Ad-C4) showed an elevated calcineurin/NFAT activity and a baseline hypertrophic phenotype but did not further develop hypertrophy during chronic Ang II/phenylephrine activation. Down-regulation of endogenous TRPC4 reversed these effects, resulting in less hypertrophy of NRCs at baseline but a markedly increased hypertrophic enlargement after chronic agonist activation. Ad-C4 NRCs did not show baseline calcineurin/NFAT activity or hypertrophy yet responded with an increased calcineurin/NFAT activity after GPCR activation. However , this effect was not translated into an increased propensity towards hypertrophy but rather fewer hypertrophy during GPCR activation. Further analyses revealed that, although hypertrophy was preserved in Ad-C4 NRCs and even attenuated in Ad-C4 NRCs, cardiomyocytes had an increased apoptosis price and thus were less viable after chronic GPCR activation. These findings suggest that TRPC4 and TRPC4 differentially impact Ca2+signals, calcineurin/NFAT signaling PF-543 and hypertrophy yet similarly impair cardiomyocyte viability during GPCR stimulation. == Introduction == Ion channels of the Transient Receptor Potential Channel-canonical type C (TRPC) family have already been suggested since key players in several cardiac disease conditions [1, 2]. They comprise 7 subunits (TRPC1-7) which are almost all expressed in the heart with respect to the developmental stage, species and occurrence of disease [1, 3]. They are assembled as tetramers in the sarcolemma of cardiomyocytes, are activated in conditions of Gq protein-coupled receptor (GPCR) activation and allow a non-selective Na+/Ca2+influx [1]. These characteristics have been considered as an ideal mixture for activating Ca2+-dependent PF-543 signaling pathways and promoting cardiac disease. For example , transgenic mice with a cardiac-specific overexpression of TRPC3 show an enhanced Ca2+influx after concomitant angiotensin II (Ang II) activation which causes an exaggerated hypertrophic growth and cardiomyopathy [4]. Similarly, hypertrophic mouse cardiomyocytes isolated after transverse aortic constriction (TAC) surgical procedure exhibit a sustained Ca2+influx which can be blocked by the manifestation of dominating negative (dn)-TRPC3 and TRPC6 mutants. This inhibition is usually coupled with fewer calcineurin and nuclear aspect of activated T-cells (NFAT) activation, an attenuated hypertrophic phenotype as well as an improvement of cardiac function [5]. Also, deficiency of TRPC1 function in the center resulted in reduced calcineurin/NFAT signaling, prevented pathological cardiac hypertrophy but preserved contractility [6]. Recently, TRPC4 provides caught attention as a important component impacting cardiomyocyte pathophysiology. Inhibition of TRPC4 with a truncated dn-TRPC4 mutant led to less pathological hypertrophy after TAC treatment [5]. This effect was associated with the absence of a store-operated Ca2+entry (SOCE) in cardiomyocytes coming from dn-TRPC4 transgenic mice in comparison to wild-type PF-543 cardiomyocytes after chronic pressure overload treatment. An additional study demonstrated that up-regulation of TRPC4 throughout myocardial infarction (MI) could cause excessive sarcoplasmic reticulum (SR) Ca2+loading and Ca2+leakage which might contribute to a depressed contractile reserve during disease [2]. Oddly enough, inhibition of TRPC4 is also connected with a reduced TRPC3-dependent Ca2+influx in cardiomyocytes [5]. Another recent study suggests a mixed activity of TRPC4 with TRPC1 PF-543 causing a background Ca2+entry, which causes an elevation of diastolic and PF-543 systolic Ca2+levels and induces reactive signaling and cardiac hypertrophy [7]. These findings JAK1 may indicate some degree of heteromerization between TRPC4 and other TRPC isoforms in the heart. The expression of different splice variants may constitute an additional critical feature for TRPC4dependent effects on heart disease. A number of TRPC4 splice variants have already been found, including TRPC4 and TRPC4 which are the most abundantly expressed and best described isoforms [8, 9]. They share a higher sequence homology but vary within a stretch of.
